NCT03424005
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Symptomatic, untreated, or actively progressing CNS metastases may be excluded from stage 2 of the study
https://ClinicalTrials.gov/show/NCT03424005